Analyst Price Targets — IDXX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| October 16, 2026 8:31 am | Matt Dellatorre | Goldman Sachs | $740.00 | $547.18 | TheFly | Idexx Laboratories initiated with a Buy at Goldman Sachs |
| August 11, 2026 9:39 am | Glen Santangelo | Barclays | $710.00 | $595.76 | TheFly | Idexx Laboratories price target lowered to $710 from $800 at Barclays |
| July 27, 2026 12:53 pm | — | UBS | $620.00 | $559.86 | TheFly | Idexx Laboratories price target lowered to $620 from $640 at UBS |
| April 28, 2026 12:16 pm | Andrea Alfonso | UBS | $640.00 | $569.17 | TheFly | Idexx Laboratories price target lowered to $640 from $730 at UBS |
| February 9, 2026 11:54 am | — | Piper Sandler | $750.00 | $644.61 | TheFly | Idexx Laboratories price target lowered to $750 from $775 at Piper Sandler |
| February 5, 2026 10:41 am | Glen Santangelo | Barclays | $800.00 | $642.94 | TheFly | Idexx Laboratories price target lowered to $800 from $850 at Barclays |
| February 3, 2026 12:07 pm | Andrea Alfonso | UBS | $730.00 | $639.60 | TheFly | Idexx Laboratories price target lowered to $730 from $750 at UBS |
| February 3, 2026 2:07 am | — | BTIG | $800.00 | $639.60 | TheFly | Idexx Laboratories price target lowered to $800 from $830 at BTIG |
| December 8, 2025 9:26 pm | Glen Santangelo | Barclays | $850.00 | $706.65 | TheFly | Idexx Laboratories initiated with an Overweight at Barclays |
| November 4, 2025 1:42 pm | — | Morgan Stanley | $805.00 | $721.04 | TheFly | Idexx Laboratories price target raised to $805 from $765 at Morgan Stanley |
Latest News for IDXX
IDXX heads into Q3 earnings with expected revenue and EPS growth, fueled by CAG Diagnostics momentum, higher testing volumes and software gains.
Diversify Advisory Services LLC lifted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 39.7% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,346 shares of the company's stock after acquiring an additional 1,234 shares during the
Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Idexx (IDXX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.